GE Healthcare has entered a deal to supply Merck & Co. with its PET imaging agent flutemetamol. Merck will use the agent in combination with its investigational Alzheimer's disease drug MK-8931. The companies think the agent, when used with PET, will help identify patients for the drug's clinical trials.

Full Story:

Related Summaries